IMRX
Immuneering Corporation5.74
-0.04-0.69%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
370.63MP/E (TTM)
-Basic EPS (TTM)
-1.79Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Immuneering launches $189M stock offering
Immuneering Corporation announced a public offering of 18,959,914 Class A common shares at $9.23 each on September 24, 2025, expecting $164.1 million in net proceeds, plus a concurrent $25 million private placement to Sanofi's Aventis Inc. for 2,708,559 shares at the same price, yielding $23.3 million net. Closings are set for September 26, 2025, subject to conditions. Funds will fuel preclinical and clinical development, extending the cash runway into 2029. Yet risks could alter outcomes.
8-K
Immuneering secures Sanofi funding
Immuneering Corporation inked a $25 million private placement with Sanofi's Aventis Inc., contingent on a public offering yielding at least $75 million gross proceeds by September 26, 2025. This bolsters funding for atebimetinib's Phase 3 pancreatic cancer trial, where interim Phase 2a data showed 86% nine-month overall survival and 53% progression-free survival in 34 patients, outpacing standard care estimates. Yet, cross-trial comparisons carry risks. Phase 3 kicks off by year-end.
8-K
Immuneering raises $25M in private placement
Immuneering Corporation announced a $25 million private placement on August 21, 2025, issuing 6.3 million shares (or pre-funded warrants) at $3.95 each, plus warrants for 2.8 million more shares at $5.50, closing around August 26. This bolsters the biotech's cash for advancing atebimetinib in pancreatic cancer trials, where early data showed 94% six-month survival versus 67% for standard care. Yet funding needs persist amid clinical risks.
ALT
Altimmune, Inc.
5.03-0.25
CUE
Cue Biopharma, Inc.
0.41-0.05
IMA
ImageneBio, Inc.
6.25+0.08
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNM
Immunome, Inc.
23.48+0.84
IMTX
Immatics N.V.
10.09+0.11
IMUX
Immunic, Inc.
0.60-0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
TIL
Instil Bio, Inc.
11.25+0.13